Ohkawa S, Mori E, Yamadori A
Rinsho Shinkeigaku. 1989 Sep;29(9):1183-5.
We investigated the efficacy of amitriptyline in seven patients with pathological laughing caused by cerebrovascular diseases. In a double-blind placebo-controlled cross-over trial comparing amitriptyline with placebo, 5 of these 7 patients were judged to have shown improvement with amitriptyline, and 1 patient improved with placebo. This difference was statistically significant. No significant side effect of amitriptyline was observed. There was no significant change between amitriptyline and placebo in both self-rating depression scale and minimental state test score. These results suggested that amitriptyline was useful in treating pathological laughing.
我们研究了阿米替林对7例脑血管疾病所致病理性发笑患者的疗效。在一项将阿米替林与安慰剂进行比较的双盲、安慰剂对照交叉试验中，这7例患者中有5例被判定使用阿米替林后病情改善，1例使用安慰剂后病情改善。这种差异具有统计学意义。未观察到阿米替林有明显副作用。在自评抑郁量表和简易精神状态检查评分方面，阿米替林与安慰剂之间均无显著变化。这些结果表明，阿米替林对治疗病理性发笑有效。
